Abstract:Background: Leukemia is a prevalent pediatric life-threatening hematologic malignancy with a poor prognosis. Targeting immune checkpoints (ICs) to reverse T cell exhaustion is a potentially effective treatment for leukemia. Tissue resident memory T (TRM) cells have been found to predict the efficacy of programmed death receptor-1 inhibitor (anti-PD-1) therapy in solid tumors. However, the IC characteristics of TRM cells in leukemia and their relationship with prognosis remain unclear. Methods: We employed multi-color flow cytometry to evaluate the frequencies of CD103+CD4+ and CD103+CD8+ T cells in the peripheral blood (PB) of patients with acute myeloid leukemia and B-cell acute lymphoblastic leukemia compared to healthy individuals. We examined the expression patterns of PD-1 and T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) within the circulating CD103+ T cell subsets affected by leukemia. To further elucidate the immunological landscape, we assessed the differentiation status of CD103+ T cells across various disease states in patients with leukemia. Results: Our findings showed a significant increase in the frequency of CD103+CD8+ T cells in the PB of patients with leukemia who had achieved complete remission (CR) compared to those in the de novo (DN) and relapsed/refractory (RR) stages. This increase was accompanied by a notable decrease in the expression levels of PD-1 and TIGIT in CD103+CD8+ T cells in the CR stage. Additionally, our analysis revealed a higher proportion of CD103+CD8+ T cells in the central memory (TCM) and effector memory (TEM) subsets of the immune profile. Notably, the proportions of CD103+ naïve T cells, CD103+ TEM, and CD103+ terminally differentiated T cells within the CD8+ T cell population were significantly elevated in patients with CR compared to those in the DN/RR stages. Conclusion: The data indicate that circulating higher frequency of CD103+CD8+ T cells with lower expression of PD-1 and TIGIT are associated with favorable outcomes in patients with leukemia. This suggests a potential role of TRM cells in leukemia prognosis and provides a foundation for developing targeted immunotherapies.

1484-P: CD57+CD8+T Cells Exhibit Distinct Features in T1D Patients with Partial Remission Phase

TGF-β-mediated crosstalk between TIGIT+ Tregs and CD226+CD8+ T cells in the progression and remission of type 1 diabetes

Reactivated CD4+Tm Cells of T1D Patients and Siblings Display an Exaggerated Effector Phenotype With Heightened Sensitivity to Activation-Induced Cell Death

A Public BCR Present in a Unique Dual-Receptor-Expressing Lymphocyte from Type 1 Diabetes Patients Encodes a Potent T Cell Autoantigen

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection

Interconnected lineage trajectories link conventional and natural killer (NK)-like exhausted CD8 + T cells beneficial in type 1 diabetes

Autoimmune CD4+ T cells fine-tune TCF1 expression to maintain function and survive persistent antigen exposure during diabetes

KIR2DL5+CD8+ T cells associate with dietary lipid intake and are active in type 1 diabetes

Regulatory T Cells and Type 1 Diabetes

Targeting the autoreactive CD8+ T-cell receptor in type 1 diabetes: Insights from scRNA-seq for immunotherapy

The Primordial Differentiation of Tumor-Specific Memory CD8+ T Cells As Bona Fide Responders to PD-1/PD-L1 Blockade in Draining Lymph Nodes.

1167-P: Immunological Landscape of Early-Onset Type 1 Diabetes—Cellular Dynamics and Molecular Pathways

Thymic self-recognition-mediated TCR signal strength modulates antigen-specific CD8+ T cell pathogenicity in non-obese diabetic mice

Reinvigorated exhausted T cells exhibit distinct features within 24 hours after PD-1 therapy

The Potential Role of Dendritic Cells in the Therapy of Type 1 Diabetes

HLA-E-restricted Regulatory CD8(+) T Cells Are Involved in Development and Control of Human Autoimmune Type 1 Diabetes.

Expression of CD1 Molecules in Peripheral Monocytes and Lymphocytes in Type 1 Diabetes Patients Aged 15-25 Years

Experimental type 1 diabetes metabolically rejuvenates CD8 T cells for improved control of tumor growth through an IGF1-IGF1R axis

Higher frequency of peripheral blood CD103+CD8+ T cells with lower levels of PD-1 and TIGIT expression related to favorable outcomes in leukemia patients

Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms